Body Surface Area (BSA) Calculator

Understanding Body Surface Area Formulas

Body surface area cannot be directly measured without complex three-dimensional imaging, so clinicians use formulas that estimate BSA from height and weight. The DuBois formula, published in 1916, was the first widely used equation: BSA = 0.007184 × weight^0.425 × height^0.725. It remains accurate but involves cumbersome exponents.

The Mosteller formula, introduced in 1987, simplifies calculation: BSA = √(weight × height / 3600). This formula is easier to compute and produces results nearly identical to DuBois in most patients. It has become the standard in many institutions and clinical guidelines.

The Haycock formula (BSA = 0.024265 × weight^0.5378 × height^0.3964) and the Gehan-George formula (BSA = 0.0235 × weight^0.51456 × height^0.42246) are alternatives validated in different patient populations. All four formulas correlate closely for typical adults; discrepancies are more noticeable in very obese or very thin individuals, infants, and children.

Clinical Applications of BSA

Chemotherapy dosing is the most common use of BSA. Many cytotoxic agents have doses expressed as mg/m², such as doxorubicin 60 mg/m² or cisplatin 75 mg/m². This approach aims to normalize drug exposure across patients of different sizes, reducing toxicity in smaller patients and ensuring efficacy in larger ones. However, recent research questions whether BSA dosing is superior to fixed dosing or weight-based dosing for all agents, particularly in obese patients where BSA may overestimate dosing needs.

Cardiac index, a measure of cardiac output normalized to body size, is calculated as cardiac output (liters per minute) divided by BSA. Normal cardiac index is 2.5-4.0 L/min/m². This allows comparison of cardiac function across patients of different sizes.

Burn assessment uses total body surface area (TBSA) to quantify the extent of burns, typically via the Rule of Nines or Lund-Browder chart. Fluid resuscitation in burns follows formulas like the Parkland formula, which calculates fluid based on TBSA percentage burned and body weight.

Certain drug dosing protocols, especially in critical care and transplant medicine, use BSA-adjusted doses. For example, some immunosuppressants and biologics are dosed per BSA to account for pharmacokinetic variability.

Limitations and Controversies

BSA assumes a proportional relationship between body size and drug clearance or distribution, but this is not always true. Obese patients have increased BSA, but many drugs do not distribute into adipose tissue proportionally, leading to overdosing if BSA alone is used. Some protocols cap chemotherapy doses or use adjusted body weight for obese patients to avoid toxicity.

Conversely, very thin or cachectic patients may be underdosed by BSA-based regimens because their lean body mass and organ function may not match their calculated BSA. Renal and hepatic function, which influence drug clearance, are not captured by BSA. Some experts advocate for incorporating renal function (creatinine clearance or eGFR) and hepatic function into dosing algorithms rather than relying solely on BSA.

Despite these limitations, BSA remains entrenched in oncology and other specialties because it provides a standardized, easily calculated metric. Until more sophisticated dosing models (like pharmacokinetic/pharmacodynamic modeling or therapeutic drug monitoring) become routine, BSA-based dosing will continue to be the default for many medications. Clinicians should use BSA as one component of dosing decisions, adjusting based on organ function, drug-specific pharmacokinetics, and patient-specific factors like age, comorbidities, and prior tolerance.